Description
HQL-79 is a selective inhibitor of hematopoietic PGD synthase. Structurally, it is a synthetic tetrazole compound originally prepared as a possible antihistamine.{11338} Subsequent evaluation in models of allergy and asthma demonstrates the HQL-79 is orally available, and inhibits the synthesis of PGD2 (Item No. 12010).{11337} HQL-79 is thus a likely lead compound for the preparation of potent, selective hematopoietic PGD synthase inhibitors.
Formal name: 4-(diphenylmethoxy)-1-[3-(1H-tetrazol-5-yl)propyl]-piperidine
Synonyms:
Molecular weight: 377.5
CAS: 162641-16-9
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Immunology & Inflammation|Allergy||Research Area|Immunology & Inflammation|Inflammatory Lipid Mediators|Prostaglandins||Research Area|Immunology & Inflammation|Pulmonary Diseases|Asthma